Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
13,105
Total Claims
$2.5M
Drug Cost
526
Beneficiaries
$4,661
Cost/Patient
Risk Score Breakdown 9/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+230%
Cost per patient vs peers
$4,661 vs $1,411 avg
+71%
Brand preference vs peers
18.1% vs 10.6% avg
Brand vs Generic
Brand: 2,273 claims · $2.1M
Generic: 10,261 claims · $305K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 260 | $344K |
| Dapagliflozin Propanediol | 115 | $158K |
| Sitagliptin Phos/Metformin Hcl | 109 | $135K |
| Sitagliptin Phosphate | 105 | $127K |
| Budesonide/Formoterol Fumarate | 124 | $92K |
| Insulin Aspart | 89 | $87K |
| Dulaglutide | 66 | $87K |
| Insulin Aspart Prot/Insuln Asp | 56 | $85K |
| Semaglutide | 74 | $84K |
| Insulin Glargine,hum.Rec.Anlog | 151 | $70K |
| Apixaban | 37 | $52K |
| Insulin Glargine,hum.Rec.Anlog | 72 | $50K |
| Abacavir/Dolutegravir/Lamivudi | 12 | $46K |
| Linagliptin | 37 | $40K |
| Insulin Lispro | 22 | $34K |
Prescribing Profile
Patient Profile
71
Avg Age
41%
Female
1.34
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data